TTNP

Titan Pharmaceuticals, Inc. [TTNP] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

TTNP Stock Summary

In the News

04:00 28 Mar 2024 TTNP

Which Industries Are Penny Stocks Investors Watching Right Now

Use these tips for finding penny stocks in different industries in 2022 The post Which Industries Are Penny Stocks Investors Watching Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

10:00 28 Mar 2024 TTNP

What to Know About Buying Penny Stocks on July 8th

Here's what you need to know about trading penny stocks on July 8th The post What to Know About Buying Penny Stocks on July 8th  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

09:15 28 Mar 2024 TTNP

Penny Stocks To Watch: Why KRKR, RMED, TYME, TTNP & ENDP Stock Are Moving

Penny stocks to watch with news The post Penny Stocks To Watch: Why KRKR, RMED, TYME, TTNP & ENDP Stock Are Moving appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

12:27 28 Mar 2024 TTNP

Titan Pharmaceuticals Raises $5.5M Via Equity

Titan Pharmaceuticals Inc TTNP has announced a private placement of 3.37 million shares and 1.29 million pre-funded warrants. Thousands of new traders are learning the ins and outs on how to find profitable trades every day with Benzinga Trading School.

08:00 28 Mar 2024 TTNP

Titan Announces Positive Results from the First Studies of TP-2021 Implant in an Established Animal Model of Chronic Pruritus

SOUTH SAN FRANCISCO, Calif., June 23, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that the in vivo study of its human kappa-opioid receptor agonist ("TP-2021," formerly JT-09) ProNeura®-based implant in an established 5'-guanidinonaltrindole (5'-GNTI) itch-induced mouse model, has demonstrated the potential to provide extended efficacy and durability in the treatment of moderate-to-severe chronic pruritus (itch).

04:30 28 Mar 2024 TTNP

Titan Pharmaceuticals Announces Filing Of 2020 Annual Report On Form 10-K

SOUTH SAN FRANCISCO, Calif., March 31, 2021 /PRNewswire/ --  Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) announced today that it has filed its annual report on Form 10-K for the fiscal year ended December 31, 2020 with the Securities and Exchange Commission ("SEC").

08:58 28 Mar 2024 TTNP

TTNP Stock Price Increases Over 15% Pre-Market: Why It Happened

The stock price of Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) is trading at over 15% pre-market. This is why it happened.

07:30 28 Mar 2024 TTNP

Positive Early Study Results Help Pave Wave for Titan Pharmaceuticals to Move Forward with its JT-09 ProNeura® Development Program

SOUTH SAN FRANCISCO, Calif., Feb. 1, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that studies of its kappa opioid agonist peptide, JT-09, has demonstrated high potency and specificity for the human kappa-opioid receptor ("KOR"). JT-09 is being developed...

09:15 28 Mar 2024 TTNP

Titan Pharmaceuticals Announces Pricing of $9.7 Million Registered Direct Offering

SOUTH SAN FRANCISCO, Calif., Jan. 15, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced it has entered into a securities purchase agreement with certain accredited institutional investors to purchase approximately $9.7 million of its common stock in a...

12:50 28 Mar 2024 TTNP

Titan Pharmaceuticals Announces Reverse Stock Split

SOUTH SAN FRANCISCO, Calif., Nov. 30, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that its Board of Directors has approved a 1-for-30 reverse stock split of the Company's common stock, which will be effective at 5:00 p.m....

TTNP Financial details

Company Rating
Neutral
Market Cap
4.74M
Income
-6.14M
Revenue
154K
Book val./share
0.54
Cash/share
0.54
Dividend
-
Dividend %
-
Employees
4
Optionable
No
Shortable
Yes
Earnings
17 May 2024
P/E
-17.47
Forward P/E
-0.8
PEG
-0.01
P/S
43.81
P/B
13.19
P/C
12.69
P/FCF
-1.05
Quick Ratio
5.16
Current Ratio
5.3
Debt / Equity
0.07
LT Debt / Equity
-
-
-
EPS (TTM)
-191.25
EPS next Y
-8.6
EPS next Q
1.58
EPS this Y
-8.43%
EPS next Y
-95.5%
EPS next 5Y
-109.1%
EPS last 5Y
-56.28%
Revenue last 5Y
-60.07%
Revenue Q/Q
300%
EPS Q/Q
-79.55%
-
-
-
-
SMA20
-12.5%
SMA50
-
SMA100
-12.5%
Inst Own
5.45%
Inst Trans
0.84%
ROA
-61%
ROE
-301%
ROC
-0.98%
Gross Margin
-187%
Oper. Margin
-5167%
Profit Margin
-3989%
Payout
-
Shs Outstand
753.32K
Shs Float
541.85K
-
-
-
-
Target Price
-
52W Range
5.0-17.0
52W High
-59.71%
52W Low
+37%
RSI
49
Rel Volume
0.84
Avg Volume
10.92K
Volume
9.19K
Perf Week
0.29%
Perf Month
-2.97%
Perf Quarter
-23.89%
Perf Half Y
-25.54%
-
-
-
-
Beta
1.343
-
-
Volatility
0.36%, 0.6%
Prev Close
-7.18%
Price
6.85
Change
-8.67%

TTNP Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
31.184.711.280.160
Net income per share
-47.59-21-5.49-0.83-0.76
Operating cash flow per share
-44.47-20.16-4.56-0.81-0.61
Free cash flow per share
-46.66-20.5-4.7-0.81-0.61
Cash per share
49.026.821.430.620.22
Book value per share
36.031.870.940.530.1
Tangible book value per share
36.031.870.940.530.1
Share holders equity per share
36.031.870.940.530.1
Interest debt per share
18.084.540.420.030.01
Market cap
150.16M87.32M248.26M198.49M209.57M
Enterprise value
145.18M86.54M243.66M192.75M206.82M
P/E ratio
-16.64-5.43-11.98-24.46-20.59
Price to sales ratio
25.424.1851.32130.073.49K
POCF ratio
-17.81-5.65-14.43-25.13-25.61
PFCF ratio
-16.97-5.56-13.99-25.06-25.61
P/B Ratio
21.9860.9470.2938.63153.76
PTB ratio
21.9860.9470.2938.63153.76
EV to sales
24.5623.9750.36126.313.45K
Enterprise value over EBITDA
-18.11-4.83-45.61-19.68-20.6
EV to operating cash flow
-17.22-5.6-14.16-24.4-25.27
EV to free cash flow
-16.41-5.51-13.73-24.33-25.27
Earnings yield
-0.06-0.18-0.08-0.04-0.05
Free cash flow yield
-0.06-0.18-0.07-0.04-0.04
Debt to equity
0.633.10.230.060.14
Debt to assets
0.310.470.10.040.05
Net debt to EBITDA
0.620.040.860.590.27
Current ratio
3.852.311.742.711.37
Interest coverage
9.3217.42-9.56-9.35K352.93
Income quality
0.930.940.940.90.8
Dividend Yield
00000
Payout ratio
-0.030000
Sales general and administrative to revenue
01.51.23.27100.57
Research and developement to revenue
1.272.011.223.7379.3
Intangibles to total assets
00000
Capex to operating cash flow
0.050.020.0300
Capex to revenue
-0.07-0.07-0.11-0.020
Capex to depreciation
-1.09-1.05-1.85-0.10
Stock based compensation to revenue
0.260.1601.0116.62
Graham number
196.4229.7310.763.151.32
ROIC
-0.61-2.62-4.58-1.51-5.88
Return on tangible assets
-0.64-1.69-2.56-1.02-2.51
Graham Net
21.3-2.120.450.350.02
Working capital
9.85M4.71M3.11M4.56M973K
Tangible asset value
6.83M1.43M3.53M5.14M1.36M
Net current asset value
6.04M219K2.77M4.37M908K
Invested capital
0.633.10.230.060.14
Average receivables
950.5K1.41M938.5K498K74K
Average payables
1.17M1.46M1.33M1.02M745K
Average inventory
631K1.13M663K310.5K199.5K
Days sales outstanding
113.37100.3766.6926.79219
Days payables outstanding
1.04K397.02968.951.46K1.29K
Days of inventory on hand
856.19282.82253.64537.41197.4
Receivables turnover
3.223.645.4713.631.67
Payables turnover
0.350.920.380.250.28
Inventory turnover
0.431.291.440.681.85
ROE
-1.32-11.23-5.87-1.58-7.47
Capex per share
-2.19-0.33-0.1400

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
03.80.0100
Net income per share
-0.18-191.01-0.11-0.11-0.02
Operating cash flow per share
-0.13-117.54-0.13-0.08-0.12
Free cash flow per share
-0.13-117.54-0.13-0.08-0.12
Cash per share
0.3218.620.080.010.54
Book value per share
0.24101.46-0.02-0.070.54
Tangible book value per share
0.24101.46-0.02-0.070.54
Share holders equity per share
0.24101.46-0.02-0.070.54
Interest debt per share
0.0213.920.010.010.04
Market cap
315.99M209.57K249.27M187.44M141.15M
Enterprise value
311.75M-2.54M248.29M187.46M133.65M
P/E ratio
-30-0.02-37.7-29.55-104.4
Price to sales ratio
79K4.112.54K187.44K35.29K
POCF ratio
-168.71-0.13-131.26-168.56-76.92
PFCF ratio
-168.71-0.13-131.26-168.56-76.92
P/B Ratio
89.010.15-798.93-181.2717.36
PTB ratio
89.010.15-798.93-181.2717.36
EV to sales
77.94K-49.812.53K187.46K33.41K
Enterprise value over EBITDA
-120.140.99-150.11-121.02-35.49
EV to operating cash flow
-166.451.61-130.75-168.58-72.83
EV to free cash flow
-166.451.61-130.75-168.58-72.83
Earnings yield
-0.01-12.24-0.01-0.010
Free cash flow yield
-0.01-7.53-0.01-0.01-0.01
Debt to equity
0.060.14-0.51-0.120.07
Debt to assets
0.030.050.070.160.06
Net debt to EBITDA
1.631.070.59-0.011.99
Current ratio
2.191.370.730.275.3
Interest coverage
-125.86108.79K77.140187.36
Income quality
0.710.621.130.75.43
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
451.525.2712.591.23K410.25
Research and developement to revenue
23328.295.72442106
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
00000
Stock based compensation to revenue
135.25-1.782.96264102.75
Graham number
0.99660.330.230.420.52
ROIC
-0.66-1.5-418.682.030.96
Return on tangible assets
-0.42-0.63-0.76-1.95-0.03
Graham Net
0.1423.97-0.09-0.110.49
Working capital
3.12M973K-662K-1.35M8.03M
Tangible asset value
3.55M1.36M-312K-1.03M8.13M
Net current asset value
3.02M908K-695K-1.35M8.03M
Invested capital
0.060.14-0.51-0.120.07
Average receivables
75K42.5K22K8.5K767.5K
Average payables
627.5K753.5K631K582K502K
Average inventory
464.5K283K106K130.5K94K
Days sales outstanding
1.1K63.537.3581034.34K
Days payables outstanding
1.52K1.39K1.19K121.561.36K
Days of inventory on hand
862.5212221.8631.56110
Receivables turnover
0.081.4212.250.110
Payables turnover
0.060.060.080.740.07
Inventory turnover
0.10.420.412.850.82
ROE
-0.74-1.885.31.53-0.04
Capex per share
00000

TTNP Frequently Asked Questions

What is Titan Pharmaceuticals, Inc. stock symbol ?

Titan Pharmaceuticals, Inc. is a US stock , located in South san francisco of Ca and trading under the symbol TTNP

What is Titan Pharmaceuticals, Inc. stock quote today ?

Titan Pharmaceuticals, Inc. stock price is $6.85 today.

Is Titan Pharmaceuticals, Inc. stock public?

Yes, Titan Pharmaceuticals, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Same Sector
Same Price Range
Similar Market Cap